This chapter discusses the Biden administration's actions to protect Alaskan wilderness from oil and gas exploration, including the prohibition of drilling in certain areas and the cancellation of existing leases. It also mentions the exemption of the Willow Oil drilling project and the Special Counsel's investigation into Hunter Biden's gun charge.
For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.